Abstract:Fragment approaches are long-established in target-based ligand discovery. Nevertheless, their full transformative potential lies dormant, because progressing hits to potency remains difficult and underserved by methodology developments, which mostly focus on screening. The only credible progression paradigm is conventional design-make-test analyse (DMTA) medicinal chemistry, which is costly and thus necessitates picking winners early, thereby effectively discarding all the other hits. We here demonstrate the workability of an alternative strategy, namely immediate large-scale exploration of diverse hit-inspired compounds. The key insight is that it is effective to cheaply parallelize large numbers of non-uniform multi-step reactions, because even without compound purification, a high-quality readout of binding is available, namely crystallography of fragment screening. This has the sensitivity to detect even low-level binding of slightly active compounds, which the targeted binding site extracts directly from crude reaction mixtures (CRMs). In this proof-of-concept study, we expand a fragment hit from a crystal-based screen of the second bromodomain of human PHIP, using array synthesis on low-cost robotics to implement 6 independent multi-step reaction routes of up to 5 steps, attempting the synthesis of 1876 diverse expansions; designs were entirely driven by synthetic tractability. Expected product was present in 1108 CRMs, as detected by automated mass spectrometry; and 22 individual products were resolved in crystal structures of CRMs added to crystals. These provided an initial SAR map, revealed pose stability in 19 and instability in 3 products, and resolved stereochemical preference. Unexpectedly, in view of the naïve design approach, one resolved compound even showed on-scale biochemical potency (IC50=34 μM) and biophysical affinity (Kd=50 μM) after resynthesis. This binding-site purification of actives (B-SPA) process is formulaic and engineerable, here yielding the output of >25 person-years in ~20 days, with solvent use reduced from >4,500L to <20L. Thus, this approach, coupled with algorithmically guided compound and reaction design and new formalisms for data analysis, lends itself to routine fragment progression.

Covalent fragment-based drug discovery for target tractability

Fragment-based Drug Discovery and Molecular Docking in Drug Design.

Advances in covalent drug discovery

Rapid Covalent-Probe Discovery by Electrophile Fragment Screening

Extended Applications of Small-Molecule Covalent Inhibitors toward Novel Therapeutic Targets

Chemical Proteomics-based Target Prioritization through a Residue Agnostic Ligandability Assessment Platform

Advanced technologies for screening and identifying covalent inhibitors

Fragment-based screening of enzyme drug targets : Microfluidic mobility shift assay improves confidence in candidate selection

Extending the Detection Limit in Fragment Screening of Proteins Using Reverse Micelle Encapsulation

Constructing Innovative Covalent and Noncovalent Compound Libraries: Insights from 3D Protein–Ligand Interactions

Applications of covalent chemistry in targeted protein degradation

Exploring protein hotspots by optimized fragment pharmacophores

Fragment-based target screening as an empirical approach to prioritising targets: a case study on antibacterials

Covalent hits and where to find them

Ligand and Target Discovery by Fragment-Based Screening in Human Cells

Identification of highly selective covalent inhibitors by phage display

Protein X-ray Crystallography and Drug Discovery

Small molecules, big targets: drug discovery faces the protein–protein interaction challenge

Design and Crystallographic Screening of a Highly Sociable and Diverse Fragment Library Towards Novel Antituberculotic Drugs

Efficient large-scale exploration of fragment hit progression by exploiting binding-site purification of actives (B-SPA) through combining multi-step array synthesis and HT crystallography.